T. Rowe Price

Selected news for the capital firm - T. Rowe Price, collected since 10/2017. This capital firm shares healthcare news with COVID-19, Medicare, OrbiMed, Medicare Advantage and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 3 Technology Mutual Funds That Should Be on Your Radar | Nasdaq Nasdaq ... has broader coverage than just hardware and software companies. Social media and Internet companies are also part of the technology landscape today.Below we share with you three top-ranked technology mutual funds, viz., T. Rowe Price Global Technology Fund PRGTX , Fidelity Select Technology Portfolio FSPTX , and BlackRock Technology Opportunities Fund Investor A Shares BGSAX . EEach has earned a Zacks Mutual Fund Rank 1 (Strong Buy) and is expected to ...
1/7/2022 StartUPDATES: New developments from healthcare startups - MedCity News MedCity News ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/5/2022 Confluence Investment Management Llc Buys iShares iBonds Dec 2030 Term Corporate ETF, Gates ... Yahoo News ... ETF, Gates Industrial Corp PLC, ISHARES TRUST, SPDR S&P 400 Mid Cap Value ETF, Blackstone Secured Lending Fund, sells Charles River Laboratories International Inc, iShares MSCI Emerging Markets ex China ETF, Accenture PLC, T. Rowe Price Group Inc, Nike Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Confluence Investment Management Llc. As of 2021Q4, Confluence Investment Management Llc owns 305 ...
1/4/2022 Desktop DNA printer maker DNA Script adds to its 9-digit VC round FierceBiotech ... Other new investors in that nine-digit fundraising included Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures.Now with a second tranche of investors, DNA Script added T. Rowe Price , Baillie Gifford, HealthCor Management, eureKARE and Irving Investors.They all joined previously returning backers—such as Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma ...
1/4/2022 eureKARE participates in DNA Script's $200 Million Series C Globe Newswire ... days or weeks to receive their genetic material from third-party service providers.eureKARE participated in the second tranche of DNA Script’s $200 million Series C financing alongside accounts and funds advised by T. Rowe Price Associates and Baillie Gifford, Healthcor Management, Irving Investors and Sino Biopharmaceutical. They joined Coatue Management, Catalio Capital Management, Fidelity Management and Research, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who ...
1/4/2022 eureKARE participates in DNA Script's $200 Million Series C Financing Yahoo News ... days or weeks to receive their genetic material from third-party service providers.eureKARE participated in the second tranche of DNA Script’s $200 million Series C financing alongside accounts and funds advised by T. Rowe Price Associates and Baillie Gifford, Healthcor Management, Irving Investors and Sino Biopharmaceutical. They joined Coatue Management, Catalio Capital Management, Fidelity Management and Research, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who ...
1/4/2022 DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche | News | bakersfield.com bakersfield.com ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/4/2022 DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche Yahoo News Accounts and funds advised by T. Rowe Price Associates, Inc. and Baillie Gifford join syndicate of investorsFunding to accelerate commercial launch of revolutionary enzymatic DNA printing technologySOUTH SAN FRANCISCO, Calif. & PARIS, January 04, 2022 --( BUSINESS WIRE )--DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced the completion of its Series C financing, raising $200 million of new capital. With this latest ...
1/4/2022 DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche | Business Wire Business Wire ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/4/2022 malvern-online.com ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/4/2022 DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche | Business | Maryville Daily Forum maryvilleforum.com ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/4/2022 DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche Business Wire ... completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC ...
1/4/2022 DNA Script Nabs $200M in Second Tranche of Series C Financing | Genomeweb genomeweb.com ... platform. Syntax is a benchtop instrument that enables on-demand DNA printing without the need for toxic chemicals or waiting for genetic material to arrive from third-party vendors.Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the latest tranche, as did Healthcor Management, eureKARE, and Irving Investors, joining Coatue Management, Catalio Capital Management, Fidelity Management & Research Company, Columbia Threadneedle Investments, Casdin Capital, and ...
12/20/2021 Senti Bio and Dynamics Special Purpose Corp. Announce Globe Newswire ... agreements -- Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds -- Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, LifeForce Capital, NEA, Parker Institute ...
12/20/2021 Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies forextv.com ... Äì Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds ‚Äì‚Äì Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, LifeForce Capital, NEA ...
12/17/2021 Upgrades and Downgrades for Friday, 12/17 tradesoftheday.com Upgrades- T. Rowe Price (TROW) upgraded by BMO Capital from Market Perform to Outperform- Invesco (IVZ) upgraded by BMO Capital from Market Perform to Outperform- Moelis (MC) upgraded by Keefe Bruyette from Market Perform to Outperform- Integra LifeSciences (IART) upgraded by JPMorgan from Underweight to Neutral- iRhythm (IRTC) upgraded by JPMorgan from Neutral to Overweight- F45 Training (FXLV) upgraded by JPMorgan from Neutral to Overweight- Genfit (GNFT) upgraded by Oddo ...
12/14/2021 T. Rowe Price Exchange-Traded Funds, Inc. Buys Microsoft Corp, Amazon. ... Yahoo News Investment company T. Rowe Price Exchange-Traded Funds, Inc. ( Current Portfolio ) buys Microsoft Corp, Amazon.com Inc, Alphabet Inc, Meta Platforms Inc, Apple Inc, sells Salesforce.com Inc, Match Group Inc, Cigna Corp, Anthem Inc, Global Payments Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, T. Rowe Price Exchange-Traded Funds, Inc.. As of 2021Q3, T. Rowe Price Exchange-Traded Funds, Inc. owns ...
12/14/2021 T. Rowe Price Group, Inc. (NASDAQ:TROW) Holdings Cut by OLD National Bancorp IN thelincolnianonline.com OLD National Bancorp IN lowered its holdings in T. Rowe Price Group, Inc. (NASDAQ:TROW) by 32.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,887 shares of the asset manager’s stock after selling 919 shares during the period. OLD National Bancorp IN’s holdings in T. Rowe Price Group were worth $371,000 at the end of ...
12/14/2021 Hills Bank & Trust Co Decreases Position in T. Rowe Price Group, Inc. (NASDAQ:TROW) - American Banking News American Banking News Hills Bank & Trust Co lowered its stake in shares of T. Rowe Price Group, Inc. (NASDAQ:TROW) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,480 shares of the asset manager’s stock after selling 1,095 shares during the period. Hills Bank & Trust Co’s holdings in T. Rowe Price Group were worth $2,652,000 ...
12/14/2021 Hills Bank & Trust Co Decreases Position in T. Rowe Price Group, Inc. (NASDAQ:TROW) zolmax.com Hills Bank & Trust Co lowered its stake in shares of T. Rowe Price Group, Inc. (NASDAQ:TROW) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,480 shares of the asset manager’s stock after selling 1,095 shares during the period. Hills Bank & Trust Co’s holdings in T. Rowe Price Group were worth $2,652,000 ...